Breast Cancer Research Stamp Reauthorization Act of 2026
- Sponsor
- Rep. Van Duyne, Beth [R-TX-24]
- Committees
- Armed Services Committee (primary)
- Last action
- Apr 16, 2026
Bottom line
This bill reauthorizes a popular semipostal stamp program, ensuring continued funding for breast cancer research through voluntary consumer contributions.
What it actually does
This bill extends the authority of the United States Postal Service (USPS) to issue the Breast Cancer Research Stamp for an additional ten years, moving the expiration date from 2027 to 2037. The semipostal stamp is sold at a price above the regular postage rate, with the excess funds dedicated to breast cancer research.
Proponents argue
Supporters argue that the Breast Cancer Research Stamp is a highly successful and non-controversial mechanism for raising significant funds for critical medical research without relying on direct taxpayer appropriations. They emphasize its voluntary nature and the broad public support for breast cancer research, which has already generated over $90 million for the cause.
Opponents contend
No organized opposition is typically raised against the reauthorization of the Breast Cancer Research Stamp, as it is a voluntary program that generates funds for a widely supported cause without direct government spending. Potential minor criticisms could relate to the administrative costs incurred by USPS or the efficiency of the fundraising mechanism compared to direct donations.
The bill is extremely short and clear, allowing for quick and easy comprehension by any reader.
Section 2
Extension of Breast Cancer Research Stamp Authority
This section amends existing law (Section 414(h) of title 39, United States Code) to change the expiration date for the United States Postal Service's authority to issue the Breast Cancer Research Stamp. The current authority is set to expire in 2027, and this bill extends it by ten years, pushing the expiration date to 2037. This ensures the continued sale of the semipostal stamp, which generates funds for breast cancer research.
Supporters argue
Supporters argue that extending this authority ensures a reliable, self-sustaining funding stream for vital breast cancer research, which has already raised over $90 million since its inception. They highlight that the program is voluntary for consumers and does not draw from general tax revenue, making it a highly efficient and publicly supported fundraising model.
Critics contend
No specific opposition is typically raised against this provision, as it extends a voluntary program for a widely supported cause. Any potential concerns might relate to the administrative burden on the USPS or the relative efficiency of this fundraising method compared to direct charitable giving, though these are generally minor.
Tradeoffs
The primary tension is balancing the public good of funding medical research with the operational mandate of the USPS. While the stamp generates funds for research, the USPS incurs some administrative costs. However, the program's success and popularity generally outweigh these minor operational considerations.